Pharmacologically, most patients wereadministered a mineralocorticoid receptor antagonist (MRA) (84.8%), a beta-blocker (74.3%), and a renin-angiotensinsystem inhibitor (RASI)/ARNI (3.9%/68.3%), with a median ARNI dose of 100 mg.More than half (52.7%) of the patients were administered the above triplecombination, while 68.7% were also administered SGLT2Is, resulting in the use ofquadruple anti-HF drugs by 37.1% cases. The gene discussed is NR3C2; the disease is hydrops fetalis.